KaliVir Immunotherapeutics

Executive Summary

KaliVir Immunotherapeutics is a private, Pittsburgh-based biotechnology company pioneering next-generation oncolytic viral immunotherapies for the treatment of cancer. The company’s lead platform, based on a novel Vaccinia Enhanced Template (VET), is designed to selectively replicate in and lyse tumor cells while stimulating a robust anti-tumor immune response. KaliVir’s lead candidate, VET3-TGI, is a modified oncolytic vaccinia virus engineered to express transgenes that enhance tumor targeting and immune activation. The company is currently advancing VET3-TGI through clinical development and has reported promising early-stage data, positioning it as a potential best-in-class oncolytic virus.

Upcoming Catalysts (preview)

• Q2 2026Initiation of Phase 1/2 trial evaluating VET3-TGI plus atezolizumab (Tecentriq) in advanced solid tumors70% success
• Q4 2026Top-line safety and preliminary efficacy data from ongoing Phase 1/2 monotherapy trial of VET3-TGI55% success
• Q3 2026Potential partnership or funding round to support late-stage development50% success